Drugs / AC480
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01245543 | Nov 2010 → Mar 2013 | cancer | Daiichi Sankyo | Withdrawn | No outcome recorded |
| Phase 1 | NCT00979173 | Nov 2009 → Oct 2010 | glioma | Annick Desjardins | Completed | No outcome recorded |
| Phase 1 | NCT00207012 | May 2004 → Feb 2006 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AC480 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00979173 ↗ |
| Known as | AC480IV | “Intravenous (IV) AC480 (AC480IV)” NCT01245543 ↗ |
| Known as | BMS-599626 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00207012 ↗ |
| Action | Inhibit | “Receptor protein-tyrosine kinase erbB-4 inhibitor” CHEMBL1645462 ↗2“Receptor protein-tyrosine kinase erbB-2 inhibitor” CHEMBL1645462 ↗ “Epidermal growth factor receptor erbB1 inhibitor” CHEMBL1645462 ↗ |
| Modality | Small molecule | — CHEMBL1645462 ↗ |
| Route | Oral | “300mg orally BID” NCT00979173 ↗ |
| Target | EGFR | “Epidermal growth factor receptor erbB1 inhibitor” CHEMBL1645462 ↗ |
| Target | ERBB2 | “Receptor protein-tyrosine kinase erbB-2 inhibitor” CHEMBL1645462 ↗ |
| Target | ERBB4 | “Receptor protein-tyrosine kinase erbB-4 inhibitor” CHEMBL1645462 ↗ |